参考文献/References:
[1] Brent GA. Clinical practice. Graves’ disease[J]. N Eng J Med, 2008, 358(24):2594-2605.
[2] 梁扩寰, 李绍白. 肝脏病学[M]. 2版. 北京:人民卫生出版社, 2003:1-1231.
[3] Biscoveanu M, Hasinski S. Abnormal results of liver function tests in patients with Graves’ disease[J]. Endocr Pract, 2000, 6(5):367-369.
[4] 冯正平, 王富华. 甲状腺机能亢进症患者肝功能改变及影响因素的初探[J]. 第三军医大学学报, 2005, 27(3):212-216.
[5] 刘燚, 袁辉, 杜媛媛, 等. 甲亢性肝功能损害的临床特点和相关因素分析. 医学信息, 2015, 28(14):27.
[6] 张小云, 钟土泉, 黄江兵. 病程长短对甲亢性肝损害患者肝功能及预后的影响[J]. 实用医技杂志, 2004, 11(6A):837-838.
[7] 吴佳玉, 邱焞功, 江南, 等. 甲亢性肝损害54例分析[J]. 四川医学, 1999, 20(6):580-581.
[8] 张晓霞. 503例甲亢性肝损害患者的临床分析[J]. 标记免疫分析与临床, 2004, 11(3):145-147.
[9] Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States[J]. Liver Transpl, 2004, 10(8):1018-1023.
[10] Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children[J]. J Clin Endocrinol Metab, 2010, 95(7):3260-3267.
[11] Wang MT, Lee WJ, Huang TY, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients:a population-based cohort study[J]. Br J Clin Pharmacol, 2014, 78(3):619-629.
[12] 潘香颖, 李慧贞. 甲状腺功能亢进症伴肝功能受损的131I 治疗疗效[J]. 国际放射医学核医学杂志, 2009, 33(3):179-180.
[13] 王洪生, 袁香坤, 张立东. 131I治疗甲亢肝损害的临床观察[J]. 放射免疫学杂志, 2007, 20(3):249.
[14] Williams KV, Nayak S, Becker D, et al. Fifty years of experience with propylthiouracil-associated hepatotoxicity:what have we learned?[J]. J Clin Endocrinol Metab, 1997, 82(6):1727-1733.
[15] 钟海蓉. 甲状腺功能亢进症131碘治疗后受损肝功的变化[J]. 四川省卫生管理干部学院学报, 2009, 28(2):150, 159.
[16] 张涛, 孙秀华, 张毛荣, 等. 131治疗甲亢性肝损害278例分析[J]. 川北医学院学报, 2004, 19(3):73-75.
[17] Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Graves’ disease[J/OL]. Thyroid Res, 2013, 6:4[2015-03-18]. http://www. ncbi. nlm. nih. gov/pmc/articles/PMC3637811.
[18] 周芳, 张春玲, 马跃华, 等. 甲亢合并白细胞减少的临床特征及转归[J]. 河南医学研究, 2014, 23(2):27-30.
[19] 蒋宁一, 林岩松, 关海霞, 等. 131I治疗格雷夫斯甲亢指南(2013版). 中华核医学与分子影像杂志, 2013, 33(2):83- 95.
[20] 郭满涛, 李亚明, 尹雅芙, 等. 甲状腺功能亢进伴白细胞减少患者放射性碘治疗早期白细胞变化随访研究[J]. 重庆医学, 2012, 41(1):28-30.
[21] Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies(ANCA):possible involvement of complement in granulocyte cytotoxicity[J]. Clin Exp Immunol, 2002, 127(1):92-98.
[22] 陆再英, 钟南山.内科学[M]. 7版. 北京:人民卫生出版社, 2008.
[23] Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan[J]. J Clin Endocrinol Metab, 2013, 98(12):4776-4783.
[24] Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage:a retrospective cohort study of agranulocytosis and pancytopenia involving 50, 385 patients with Graves’ disease[J]. J Clin Endocrinol Metab, 2012, 97(1):E49-E53.
[25] Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis:special reference to normal white blood cell count agranulocytosis. Thyroid, 2004, 14(6):459-462.
[26] Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily[J]. Thyroid, 2009, 19(6):559-563.
[27] Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease[J]. J Clin Endocrinol Metabo, 2007, 92(6):2157-2162.
[28] 蒋宁一, 匡安仁, 谭建, 等. 131I治疗Graves甲亢专家共识(2010年)[J]. 中华核医学杂志, 2010, 30(5):346-351.
[29] 李小平, 何云南, 胡庆武. 131I治疗甲亢患者疗效观察及其对外周血液的影响[J]. 放射免疫学杂志, 2004, 17(6):473-476.
[30] 谭天秩. 临床核医学[M]. 2版. 北京:人民卫生出版社, 2003:1218-1250.
[31] 黄际远, 宋文忠, 戴庆靖, 等. Graves甲亢伴白细胞减少患者131I治疗[J]. 临床血液学杂志, 2012, 25(1):42-43.
[32] 石丽红, 蒋宁一, 孙云凤, 等. 格雷夫斯甲亢合并白细胞减少患者131I治疗临床分析[J]. 中华核医学与分子影像杂志, 2013, 33(2):120-123.
[33] 张王峰, 叶常青, 袁梦晖, 等. 131碘内照射治疗对甲状腺功能亢进患者白细胞的影响[J]. 华北国防医药, 2010, 22(3):208-210.
[34] 许泽清, 邓俊, 唐彩华. 131I治疗ATD治疗后白细胞减少Graves病近期疗效观察[J]. 中国实用医药, 2012, (10):109-110.
[35] 文晓琴, 欧阳良, 胡健康, 等. 碳酸锂联合131I治疗Graves病合并白细胞减少症的效果分析[J]. 天津医药, 2014, 42(8):782-785.
[36] 许泽清, 贾晓娟, 唐彩华. 碳酸锂联合131I治疗合并白细胞减少的严重Graves病近期疗效观察[J]. 实用医技杂志, 2012, 19(7):689-690.
[37] 迟志波, 孙宝莹, 闫萍. 泼尼松治疗Graves病甲亢合并白细胞减少疗效观察[J]. 山东医药, 2005, 45(34):28.
相似文献/References:
[1]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[4]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[5]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[6]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[7]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[8]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[9]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
[10]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[15]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(6):143.
[16]袁卫红,张怡,罗志航.内分泌性眼病患者外周血中白细胞介素6和胰岛素样生长因子1水平变化的研究[J].国际放射医学核医学杂志,2008,32(3):167.
YUAN Wei-hong,ZHANG Yi,LUO Zhi-hang.The investigation of cytokine level in peripheral blood of patients with thyroid eye disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):167.
[17]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):325.
[18]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]